Live Webinar Sept 20th, 2pm EST With Dr Carman Giacomantonio, MD, MSc., FRCSC

Join us as CEO David Regan discusses Sona’s recently announced study with principal investigator Dr. Carman Giacomantonio MD, MSc., FRCSC on September 20th. The study will assess Sona’s developing ‘THT’ cancer therapy for efficacy and its ability to act as a catalyst to generate immune responses.

In this session, Dr. Carman will detail the research initiative that is to be undertaken with The Giacomantonio Immuno-Oncology Research Group.

Register for the opportunity to gain insights and ask questions of management and Dr. Giacomantonio.

Subscribe to Our Newsletter

Download the Company Presentation

Read or Download the Latest White Paper

The Case for Hyperthermia Thermal Therapy for Cancer - White Paper - Sona Nanotech

The Case for “Hyperthermia” Thermal Therapy for Cancer